ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 075,68
0,99%
Dow Jones
38 884,26
0,08%
DAX
18 430,05
1,42%
Brent Oil
82,865
-0,73%
Bitcoin
62 847,41
-0,51%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Spero Therapeutics Inc (SPRO)

  7. Spero Therapeutics Inc (SPRO) Actualités

SPRO

Spero Therapeutics (SPRO)

Spero Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SPRO
DateHeureSourceTitreSymboleSociété
06/03/202414h05GlobeNewswire Inc.Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024NASDAQ:SPROSpero Therapeutics Inc
28/02/202414h05GlobeNewswire Inc.Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial InfectionsNASDAQ:SPROSpero Therapeutics Inc
26/02/202414h05GlobeNewswire Inc.Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare ConferenceNASDAQ:SPROSpero Therapeutics Inc
09/02/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
06/02/202402h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
05/02/202422h50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SPROSpero Therapeutics Inc
31/01/202422h05GlobeNewswire Inc.Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SPROSpero Therapeutics Inc
05/01/202414h05GlobeNewswire Inc.Spero Therapeutics Provides Corporate Update and 2024 OutlookNASDAQ:SPROSpero Therapeutics Inc
02/01/202414h05GlobeNewswire Inc.Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract InfectionsNASDAQ:SPROSpero Therapeutics Inc
15/11/202322h15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
13/11/202322h50Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SPROSpero Therapeutics Inc
13/11/202322h05GlobeNewswire Inc.Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business UpdateNASDAQ:SPROSpero Therapeutics Inc
13/11/202322h02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SPROSpero Therapeutics Inc
13/11/202312h45IH Market NewsMonday’s Wall Street Highlights: Boeing, Novo Nordisk, Moody’s, StoneCo, and moreNASDAQ:SPROSpero Therapeutics Inc
06/11/202314h05GlobeNewswire Inc.Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023NASDAQ:SPROSpero Therapeutics Inc
01/11/202321h05GlobeNewswire Inc.Spero Therapeutics to Present at Upcoming November Investor ConferencesNASDAQ:SPROSpero Therapeutics Inc
01/11/202313h05GlobeNewswire Inc.Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business OfficerNASDAQ:SPROSpero Therapeutics Inc
16/10/202322h01Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SPROSpero Therapeutics Inc
20/09/202322h05GlobeNewswire Inc.Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor ConferenceNASDAQ:SPROSpero Therapeutics Inc
06/09/202314h05GlobeNewswire Inc.Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:SPROSpero Therapeutics Inc
01/09/202322h11Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SPROSpero Therapeutics Inc
01/09/202322h08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SPROSpero Therapeutics Inc
22/08/202323h27Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SPROSpero Therapeutics Inc
10/08/202322h05GlobeNewswire Inc.Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business UpdateNASDAQ:SPROSpero Therapeutics Inc
03/08/202314h05GlobeNewswire Inc.Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023NASDAQ:SPROSpero Therapeutics Inc
31/07/202318h59Dow Jones NewsSpero Therapeutics Shares Rise 14% After Special Protocol Assessment Agreement With FDANASDAQ:SPROSpero Therapeutics Inc
31/07/202314h51Dow Jones NewsSpero Therapeutics in Special Protocol Assessment Agreement for Phase 3 Trial of Tebipenem HBrNASDAQ:SPROSpero Therapeutics Inc
31/07/202314h05GlobeNewswire Inc.Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBrNASDAQ:SPROSpero Therapeutics Inc
14/06/202314h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SPROSpero Therapeutics Inc
14/06/202314h13Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SPROSpero Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SPRO

Dernières Valeurs Consultées

NASDAQ
MSFT
Microsoft
EU
AI
Air Liquide
COIN
ETHUSD
Ethereum
EU
SGO
Cie de SaintGobain
NASDAQ
AMZN
Amazon.com
NASDAQ
AAPL
Apple
EU
GLE
Societe Generale
USI
USTECH100
US Tech 100
EU
LR
Legrand
EU
BN
Danone
EU
MC
Lvmh Moet Hennessy Louis...
EU
VIV
Vivendi
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés